A 38-year-old woman from Mumbai presents with progressive fatigue and dyspnea for 3 months. On examination, she has mild splenomegaly. Her CBC shows Hb 7.2 g/dL, MCV 72 fL, and RBC count 5.8 × 10¹²/L. Peripheral blood smear reveals microcytic RBCs with target cells, polychromasia, and occasional nucleated RBCs. Serum ferritin is 1200 ng/mL and serum iron is elevated. What is the most appropriate next step in management?

Explanation

## Clinical Interpretation: Thalassemia with Iron Overload ### Morphologic Clues in This Case **Key Point:** The combination of microcytic anemia (MCV 72 fL), elevated RBC count (5.8 × 10¹²/L), target cells, polychromasia, nucleated RBCs, splenomegaly, markedly elevated ferritin (1200 ng/mL), and elevated serum iron is the classic presentation of **thalassemia (major or intermediate) with significant iron overload**. **High-Yield:** In thalassemia, iron overload occurs due to: 1. Repeated blood transfusions (transfusional siderosis) 2. Increased gastrointestinal iron absorption driven by ineffective erythropoiesis (hepcidin suppression) ### Why Iron Chelation Is the Most Appropriate Next Step **Clinical Pearl:** With a serum ferritin of **1200 ng/mL**, this patient has established iron overload. Iron chelation therapy is indicated when: - Serum ferritin consistently **>1000 ng/mL** (WHO/TIF guidelines) - Liver iron concentration (LIC) >7 mg Fe/g dry weight Iron overload causes progressive **cardiac, hepatic, and endocrine organ damage** (hemosiderosis). Delaying chelation risks irreversible end-organ injury. The diagnosis of thalassemia is already strongly supported by the clinical and laboratory picture; bone marrow biopsy is NOT required before initiating chelation. **Standard chelation agents (KD Tripathi / TIF Guidelines):** - **Deferasirox** (oral) — first-line in most settings - **Deferoxamine** (subcutaneous infusion) — gold standard, especially in children - **Deferiprone** (oral) — particularly effective for cardiac iron ### Why the Other Options Are Incorrect | Option | Reason Incorrect | |--------|-----------------| | A – Folic acid supplementation | Addresses megaloblastic anemia; not the priority here with established iron overload | | C – Bone marrow biopsy | Not required to confirm thalassemia or to initiate chelation; diagnosis is clinically evident | | D – Blood transfusion to Hb >10 | Transfusion without chelation would worsen iron overload; Hb 7.2 g/dL with compensated picture does not mandate urgent transfusion as the *next* step | ### Management Algorithm ``` Thalassemia + Ferritin >1000 ng/mL ↓ Iron Chelation Therapy (Deferasirox / Deferoxamine) ↓ Monitor ferritin, LIC (MRI T2*), cardiac function ↓ Adjust chelation dose accordingly ``` **High-Yield:** Per the **Thalassaemia International Federation (TIF) 2021 Guidelines** and **Harrison's Principles of Internal Medicine (21e)**, iron chelation should be initiated promptly once ferritin exceeds 1000 ng/mL to prevent hemosiderosis-related organ damage. Bone marrow biopsy is not a prerequisite for this decision. [cite: Harrison's 21e Ch 99; KD Tripathi Essentials of Medical Pharmacology 8e; TIF Guidelines for Management of Transfusion-Dependent Thalassaemia 2021]